| scholarly article | Q13442814 |
| P50 | author | Jeffery D. Molkentin | Q54858774 |
| P2093 | author name string | Jian Xu | |
| Allen York | |||
| Joerg Heineke | |||
| Mannix Auger-Messier | |||
| Michelle Sargent | |||
| Stephen Welle | |||
| P2860 | cites work | Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee | Q22306347 |
| Myostatin regulates cardiomyocyte growth through modulation of Akt signaling | Q24614013 | ||
| Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member | Q28237287 | ||
| Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct | Q33864336 | ||
| Induction of cachexia in mice by systemically administered myostatin. | Q33959328 | ||
| Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy | Q33974366 | ||
| Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study | Q34187927 | ||
| Wasting as independent risk factor for mortality in chronic heart failure | Q34421966 | ||
| Insulin-like growth factor-1 mediates stretch-induced upregulation of myostatin expression in neonatal rat cardiomyocytes | Q34446121 | ||
| Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy | Q35088393 | ||
| Regulation of muscle mass by myostatin | Q35912777 | ||
| Cardiac cachexia | Q35932382 | ||
| Muscle wasting in cardiac cachexia | Q36146080 | ||
| Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure | Q36620881 | ||
| Transcriptional effects of chronic Akt activation in the heart. | Q38290130 | ||
| Myostatin, activin receptor IIb, and follistatin-like-3 gene expression are altered in adipose tissue and skeletal muscle of obese mice | Q38292770 | ||
| Muscle growth after postdevelopmental myostatin gene knockout | Q42505111 | ||
| Selective expression of Cre recombinase in skeletal muscle fibers | Q44231113 | ||
| Functional improvement of dystrophic muscle by myostatin blockade. | Q44234792 | ||
| Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin | Q44489665 | ||
| Myofibrillar protein synthesis in myostatin-deficient mice | Q46747994 | ||
| Spotlight: Arjang Ruhparwar, MD. Interview by Richard Hoey | Q48324446 | ||
| Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. | Q51820504 | ||
| Embryonic expression of an Nkx2-5/Cre gene using ROSA26 reporter mice. | Q52125445 | ||
| Myostatin, a transforming growth factor-? superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct | Q56874784 | ||
| Selective expression of Cre recombinase in skeletal muscle fibers | Q58949686 | ||
| Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure | Q68084268 | ||
| Abnormalities of skeletal muscle in patients with chronic heart failure | Q69819089 | ||
| Modulating skeletal muscle mass by postnatal, muscle-specific inactivation of the myostatin gene | Q73323592 | ||
| Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure | Q80249940 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| P304 | page(s) | 419-25 | |
| P577 | publication date | 2010-01-26 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure | |
| P478 | volume | 121 |
| Q34362078 | Aerobic exercise training prevents heart failure-induced skeletal muscle atrophy by anti-catabolic, but not anabolic actions |
| Q42023617 | Alcoholic Myopathy: Pathophysiologic Mechanisms and Clinical Implications |
| Q34520504 | Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation |
| Q41188450 | Body mass index is associated with prognosis in Japanese elderly patients with atrial fibrillation: an observational study from the outpatient clinic. |
| Q57814839 | Body mass loss is a surrogate marker of frailty in heart failure |
| Q37960096 | Cachexia and sarcopenia: emerging syndromes of importance in dogs and cats |
| Q37723852 | Can exercise teach us how to treat heart disease? |
| Q26744140 | Cardiac cachexia: hic et nunc |
| Q28250153 | Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload |
| Q34684837 | Cardiac myocyte-specific ablation of follistatin-like 3 attenuates stress-induced myocardial hypertrophy |
| Q37140393 | Cardiac myostatin upregulation occurs immediately after myocardial ischemia and is involved in skeletal muscle activation of atrophy. |
| Q37076096 | Cardiac-Secreted Factors as Peripheral Metabolic Regulators and Potential Disease Biomarkers. |
| Q47916949 | Cardiomyokines from the heart |
| Q36566423 | Circulating Growth Differentiation Factor 11/8 Levels Decline With Age. |
| Q61444832 | Dilated cardiomyopathy-mediated heart failure induces a unique skeletal muscle myopathy with inflammation |
| Q57652376 | Effects of an ActRIIB.Fc Ligand Trap on Cardiac Function in Simian Immunodeficiency Virus-Infected Male Rhesus Macaques |
| Q30301118 | Enhanced skeletal muscle expression of extracellular superoxide dismutase mitigates streptozotocin-induced diabetic cardiomyopathy by reducing oxidative stress and aberrant cell signaling |
| Q26991985 | Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem |
| Q36179111 | Finding good biomarkers for sarcopenia |
| Q28267548 | GDF11 does not rescue aging-related pathological hypertrophy |
| Q92445786 | Growth Differentiation Factor-8 (GDF8)/Myostatin is a Predictor of Troponin I Peak and a Marker of Clinical Severity after Acute Myocardial Infarction |
| Q34880903 | Heart over mind: metabolic control of white adipose tissue and liver |
| Q35964567 | Higher Plasma Myostatin Levels in Cor Pulmonale Secondary to Chronic Obstructive Pulmonary Disease |
| Q35049028 | Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients |
| Q40908124 | Impact of cardiac resynchronization therapy-defibrillator implantation on the association between body mass index and prognosis in patients with heart failure. |
| Q51581859 | Increased plasma myostatin in heart failure. |
| Q42580068 | Interplay between heart and skeletal muscle disease in heart failure: the 2011 George E. Brown Memorial Lecture |
| Q34520509 | Is Growth Differentiation Factor 11 a Realistic Therapeutic for Aging-Dependent Muscle Defects? |
| Q38743215 | Management of Heart Failure with Preserved Ejection Fraction: Current Challenges and Future Directions |
| Q38052031 | Metabolic and structural impairment of skeletal muscle in heart failure |
| Q38888119 | MicroRNAs, heart failure, and aging: potential interactions with skeletal muscle. |
| Q36179105 | Molecular and cellular mechanisms of skeletal muscle atrophy: an update. |
| Q39094397 | Molecular mechanism of sarcopenia and cachexia: recent research advances. |
| Q37138465 | Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia |
| Q28068034 | Molecular pathways leading to loss of skeletal muscle mass in cancer cachexia--can findings from animal models be translated to humans? |
| Q49183956 | Muscle wasting and sarcopenia in heart failure and beyond: update 2017. |
| Q38303979 | Muscle wasting in disease: molecular mechanisms and promising therapies |
| Q39322768 | Muscle wasting is associated with reduced exercise capacity and advanced disease in patients with chronic heart failure |
| Q34994430 | Myostatin and IGF-I signaling in end-stage human heart failure: a qRT-PCR study. |
| Q43227383 | Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice |
| Q24609841 | Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting |
| Q34023157 | Myostatin is elevated in congenital heart disease and after mechanical unloading |
| Q30358722 | Myostatin mediates abdominal aortic atherosclerosis progression by inducing vascular smooth muscle cell dysfunction and monocyte recruitment. |
| Q42872681 | Myostatin up-regulation is associated with the skeletal muscle response to hypoxic stimuli |
| Q27308903 | Overexpression of Latent TGFβ Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGFβ |
| Q30427538 | PGC-1α promotes nitric oxide antioxidant defenses and inhibits FOXO signaling against cardiac cachexia in mice |
| Q36698663 | Paracrine and endocrine modes of myostatin action |
| Q57492462 | Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases |
| Q51504349 | Plasma myostatin levels are related to the extent of right ventricular dysfunction in exacerbation of chronic obstructive pulmonary disease. |
| Q47303605 | Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle. |
| Q38628641 | Prevention of liver cancer cachexia-induced cardiac wasting and heart failure |
| Q51664676 | Proteomic profiling of muscle fibre type shifting in neuromuscular diseases. |
| Q39019268 | Publication trends in cachexia and sarcopenia in elderly heart failure patients |
| Q42552906 | Questions and Answers About Myostatin, GDF11, and the Aging Heart |
| Q46243879 | RNA-seq reveals transcriptome changes in goats following myostatin gene knockout. |
| Q36421043 | Research on cachexia, sarcopenia and skeletal muscle in cardiology |
| Q38977192 | Respiratory muscle weakness in the Zucker diabetic fatty rat. |
| Q34001370 | SMAD3 augments FoxO3-induced MuRF-1 promoter activity in a DNA-binding-dependent manner |
| Q92702018 | Sarcopenia and Heart Failure |
| Q36028202 | Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass |
| Q28066237 | Sarcopenia in heart failure: mechanisms and therapeutic strategies |
| Q36683918 | Sarcopenic obesity and the pathogenesis of exercise intolerance in heart failure with preserved ejection fraction |
| Q34536058 | Silencing Myostatin Using Cholesterol-conjugated siRNAs Induces Muscle Growth |
| Q38596709 | Skeletal Muscle Changes in Chronic Cardiac Disease and Failure. |
| Q37994970 | Skeletal muscle abnormalities in chronic heart failure |
| Q91686461 | Skeletal muscle alterations in tachycardia-induced heart failure are linked to deficient natriuretic peptide signalling and are attenuated by RAS-/NEP-inhibition |
| Q38065902 | Skeletal muscle protein metabolism in human heart failure |
| Q26781640 | Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training |
| Q60909015 | Skeletal muscle wasting in chronic heart failure |
| Q40640594 | Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice. |
| Q34552864 | Supraphysiological levels of GDF11 induce striated muscle atrophy |
| Q35118594 | Synergistic and antagonistic interplay between myostatin gene expression and physical activity levels on gene expression patterns in triceps Brachii muscles of C57/BL6 mice |
| Q35045905 | Taking pressure off the heart: the ins and outs of atrophic remodelling |
| Q35739702 | Targeting the myostatin signaling pathway to treat muscle wasting diseases |
| Q28244342 | Telethonin deficiency is associated with maladaptation to biomechanical stress in the mammalian heart |
| Q28397317 | The Role of Exercise in Cardiac Aging: From Physiology to Molecular Mechanisms |
| Q87829005 | The TGFβ superfamily in cardiac dysfunction |
| Q37637929 | The effect of eight weeks resistance and aerobic training on myostatin and follistatin expression in cardiac muscle of rats. |
| Q41717334 | The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy. |
| Q35223987 | The role of myostatin in muscle wasting: an overview |
| Q37238641 | Through thick and thin: a circulating growth factor inhibits age-related cardiac hypertrophy |
| Q37878253 | Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis. |
| Q35128695 | Treating cancer cachexia to treat cancer |
| Q104802877 | Understanding the common mechanisms of heart and skeletal muscle wasting in cancer cachexia |
| Q38017586 | Unraveling new mechanisms of exercise intolerance in chronic heart failure: role of exercise training |
| Q87166267 | [Obesity and cardiac cachexia in chronic heart failure] |
Search more.